Skip to content
OpenCapital
Get started

Indivior Pharmaceuticals, Inc. INDV Current ratio

Current ratio at other companies

Alkermes logo
AlkermesALKS
2.3×-1.1×
JAN
Janus Living JAN
0.8×0.0×

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%
Enterprise value$4.86B+242%
P/E18×—
P/S3.5×+2.3×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Return on equity-117%—
Debt / equity-3.5×—

Where this comes from

Calculated from Indivior Pharmaceuticals, Inc. ’s reported figures.

total current assets/total current liabilities=0.9×

Based on the most recent quarter.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's current ratio?
Indivior Pharmaceuticals, Inc. (INDV) reported current ratio of 0.9× in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's current ratio changed year-over-year?
Indivior Pharmaceuticals, Inc. 's current ratio decreased by 2.5% year-over-year, from 0.9× to 0.9×.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's current ratio?
Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc. 's current ratio has grown at a -14.7% compound annual growth rate (CAGR), from 1× to 0.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.